<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Bristol-Myers Squibb continues to deliver excellent results, making the stock one of the best deep value picks in the biopharma sector. Management expects solid growth rates through 2029 thanks to strong pipeline despite patent losses from Revlimid and Pomalyst.
...read full article on Seeking Alpha
